CSPC Pharma to Support Drug Discovery Work at Columbia University

CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) will collaborate with Columbia University of New York City to develop drugs that inhibit aldose reductase, an enzyme that causes eye and nerve damage. Aldose reductase inhibitor drugs may treat a number of serious conditions. CSPC will underwrite research carried out by the Organic Chemistry Collaborative Center at Columbia’s Department of Medicine. CSPC will have the right to develop and commercialize OCCC-discovered molecules, which are initially intended for the China market. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.